The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC).
Z. Meng
No relevant relationships to disclose
L. Liu
No relevant relationships to disclose
Y. Shen
No relevant relationships to disclose
P. Yang
No relevant relationships to disclose
L. Cohen
No relevant relationships to disclose
Y. Huo
No relevant relationships to disclose
Q. Zhao
No relevant relationships to disclose
C. S. Ng
No relevant relationships to disclose
D. Z. Chang
No relevant relationships to disclose
C. R. Garrett
No relevant relationships to disclose